Order Article Reprints

Hanel W, Shindiapina P, Bond DA, Sawalha Y, Epperla N, Voorhees T, Welkie RL, Huang Y, Behbehani GK, Zhang X, et al. A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Cancers. 2023; 15(5):1437. https://doi.org/10.3390/cancers15051437

Hanel, Walter, Polina Shindiapina, David A. Bond, Yazeed Sawalha, Narendranath Epperla, Timothy Voorhees, Rina Li Welkie, Ying Huang, Gregory K. Behbehani, Xiaoli Zhang, and et al. 2023. "A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma" Cancers 15, no. 5: 1437. https://doi.org/10.3390/cancers15051437

Hanel, W., Shindiapina, P., Bond, D. A., Sawalha, Y., Epperla, N., Voorhees, T., Welkie, R. L., Huang, Y., Behbehani, G. K., Zhang, X., McLaughlin, E., Chan, W. K., Brammer, J. E., Jaglowski, S., Reneau, J. C., Christian, B. A., William, B. M., Cohen, J. B., Baiocchi, R. A., ... Alinari, L. (2023). A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Cancers, 15(5), 1437. https://doi.org/10.3390/cancers15051437